Format

Send to

Choose Destination
J Intern Med. 2016 Jun;279(6):541-62. doi: 10.1111/joim.12470. Epub 2016 Jan 8.

The immune system and cancer evasion strategies: therapeutic concepts.

Author information

1
Institute of Pathology, University Hospital Basel, Basel, Switzerland.
2
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
3
Department of Biomedicine, Cancer Immunology Laboratory, University of Basel, Basel, Switzerland.
4
Department of Surgery, University Hospital Basel, Basel, Switzerland.

Abstract

The complicated interplay between cancer and the host immune system has been studied for decades. New insights into the human immune system as well as the mechanisms by which tumours evade immune control have led to the new and innovative therapeutic strategies that are considered amongst the medical breakthroughs of the last few years. Here, we will review the current understanding of cancer immunology in general, including immune surveillance and immunoediting, with a detailed look at immune cells (T cells, B cells, natural killer cells, macrophages and dendritic cells), immune checkpoints and regulators, sialic acid-binding immunoglobulin-like lectins (Siglecs) and other mechanisms. We will also present examples of new immune therapies able to reverse immune evasion strategies of tumour cells. Finally, we will focus on therapies that are already used in daily oncological practice such as the blockade of immune checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) in patients with metastatic melanoma or advanced lung cancer, or therapies currently being tested in clinical trials such as adoptive T-cell transfer.

KEYWORDS:

immune checkpoints; immune regulators; immunoediting; immunosurveillance; siglecs

PMID:
26748421
DOI:
10.1111/joim.12470
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center